



ASX ANNOUNCEMENT

11 SEPTEMBER 2024

UNIVERSITY OF PENNSYLVANIA JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL

- CHM CDH17 is a world leading CDH17-directed CAR-T cell therapy
- University of Pennsylvania is a world leader in developing CAR T cell therapies
- The Phase 1 portion of this clinical trial is planned for up to 15 subjects
- The study is recruiting patients with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours

Sydney, Australia, 11 September 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), is pleased to announce that University of Pennsylvania (Penn) is open to enrol patients in the Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy.

The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.

“We are excited to have Penn on board, where the technology was developed.” said Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics.

Jennifer Eads, MD, the study’s principal investigator from University of Pennsylvania said that “After over a decade of development here at Penn, it is thrilling to be advancing CHM CDH17 as a potential new medicine for cancer patients.”

Additional clinical trial sites are anticipated to open to enrolment in the second half of 2024.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 clinical stage programs.



CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: + 61 498 966 180
E: investor@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au